Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07132775 · ClinicalTrials.gov registry record · NA

Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain

A NA study of Multiple Sclerosis and Fibromyalgia, sponsored by Shirley Ryan AbilityLab.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT07132775: Recruiting NA study of Multiple Sclerosis and Fibromyalgia, sponsored by Shirley Ryan AbilityLab.

NCT07132775 is a NA study of Multiple Sclerosis and Fibromyalgia that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 15 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07132775, a NA study of Multiple Sclerosis and Fibromyalgia, is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and/or pain.

Primary Outcome

The Berg Balance Scale is a 14-item objective measure that assesses static balance and falls risk. The functional abilities that are assessed include sitting and standing balance, transfers, altered bases of support, reaching, turning, and closing eyes.Scores range from 0 - 56, with higher scores indicating improved balance.

Interventions

  • DEVICE Active full-body stimulation
  • OTHER Sham full-body stimulation

Study Locations (1)

Illinois

  • Shirley Ryan AbilityLab - Chicago

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-07-23
Est. Completion 2027-07
Phase NA
Shirley Ryan AbilityLab

138 total trials

What NCT07132775 shows while recruiting

NCT07132775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower).

The record links to 4 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Active full-body stimulation is the first listed.

NCT07132775 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT07132775 about?

NCT07132775 is a clinical study titled "Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain". The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and/or pain.

What is the current status of trial NCT07132775?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-07-23. Estimated completion is 2027-07.

What conditions does trial NCT07132775 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Fibromyalgia, Neurologic Disorder, Neuromuscular Disorders.

What interventions are being tested in trial NCT07132775?

The interventions under investigation include: Active full-body stimulation (DEVICE), Sham full-body stimulation (OTHER).

Who is sponsoring clinical trial NCT07132775?

This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07132775 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07132775's enrollment target sits among peer trials

15 284th of 315 higher than 26 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07132775, the US trial registry maintained by the National Library of Medicine. NCT07132775 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.